Don't close this page .. Test is protected .. Answers cannot be changed .. We try now to connect to save and correct your answers.
Connection trial number:
If this message persists for long, please check your internet connection.
This test is monitored
Switching to another webpage or any other program is considered a cheating behavior and your test may be automatically terminated.
Okay
Important Notice
If you moved to the next question, you will not be able to come back to this question again.
Cancel
Move to next question
Final exam لمادة موضوعات مختارة في علم الادوية
Student data
×
Student data
Student name: ***
Student number: ***
Class or section: ***
Test instructions
×
Test instructions
عدد الاسءلة هي 63 سؤال
Page direction
×
Change page direction
Right to left
Left to right
Q1
Score: 0.5
A- pharmaceutic interaction
B- pharmacodynamic interaction
C- pharmacokinetic interaction
Q2
Score: 0.5
صح
خطأ
Q3
Score: 0.5
A- mental retardation
B- Mutagenesis
C- is seen in up to 25% of the fetuses with first - trimester exposure to coumarins
D- carcinogenesis
Q4
Score: 0.5
صح
خطأ
Q5
Score: 0.5
A- spontaneous
B- route of exposure
C- species
D- sex of test animal formulation
Q6
Score: 0.5
صح
خطأ
Q7
Score: 0.5
A- Aspirin
B- sulfonamide
C- chloramphenicol
D- Tetracycline
Q8
Score: 0.5
A- result in polar
B- water soluble
C- oxidase
D- conjugation
Q9
Score: 0.5
A- 5- 10 years
B- 1 month
C- 15- 25 years
D- 9 month to 3 years
Q10
Score: 0.5
A- poly pharmacy
B- multiple disease state
C- increase severity of illness
D- B+ C
E- all the above
Q11
Score: 0.5
A- treatment of pre- existing chronic disorder
B- always use drugs which have been widely used
C- over the counter
D- drugs for medical condition prior to confirmation of pregnancy
Q12
Score: 0.5
صح
خطأ
Q13
Score: 0.5
A- gene
B- protein
C- cell
D- tissue
Q14
Score: 0.5
A- digoxin
B- NSAIDS
C- Atropine- like drugs
Q15
Score: 0.5
A- phase I
B- phase II
C- phaseI and II and III and IV
D- phase III
Q16
Score: 0.5
A- fetal period
B- organogenesis
C- Blastogenesis
D- non the above
Q17
Score: 0.5
A- drug action
B- cell
B- tissue
C- system
Q18
Score: 0.5
A- In vivo
B- in human
C- in animal
D- in vitro
Q19
Score: 0.5
Q20
Score: 0.5
Q21
Score: 0.5
A- chemical modification of known molecule
B- biotechnology and cloning
C- random screening for biological activity of large numbers of natural
D- all the above
Q22
Score: 0.5
A- category A
B- category B
C- category c
D- category D
E- category x
Q23
Score: 0.5
A- animal
B- human
C- in vivo
Q24
Score: 0.5
صح
خطأ
Q25
Score: 0.5
صح
خطأ
Q26
Score: 0.5
A- FDA
B- NMR
C- IND
Q27
Score: 0.5
صح
خطأ
Q28
Score: 0.5
A- digoxin
B- TCAS
C- Atropine like drugs
Q29
Score: 0.5
A- Clark's Rule
B- Youngs Rule
C- creatinine clearance
D- non the above
Q30
Score: 0.5
A- urinary retention
B- hyperglycemia
C- heart block
D- GI hemorrhage
Q31
Score: 0.5
Q32
Score: 0.5
Q33
Score: 0.5
صح
خطأ
Q34
Score: 0.5
Q35
Score: 0.5
A- vaccination
B- blood transfusion
C- transplantation
D- drug therapy
Q36
Score: 0.5
A- Elderly people
B- Infant
C- they are the major consumer of drug
D- include polypharmacy
Q37
Score: 0.5
A- chemical development
B- safety assessment
C- drug metabolism
D- all the above
Q38
Score: 0.5
A- factor including the vascular perfusion
B- By 6 weeks of age
C- such as penicillin
D- are reduced by 50% in premature
Q39
Score: 0.5
صح
خطأ
Q40
Score: 0.5
A- conducting a clinical trial
B- Analyzing the outcome of a clinical trial
C- Givrine permission so clinical trial
D- non the above
Q41
Score: 0.5
A- nasal hypoplasia
B- bone stippling on X- Ray
C- depressed bridge of nose
D- all the above
E- non the above
Q42
Score: 0.5
A- phase -1
B- phase- 2
Q43
Score: 0.5
A- strength of hypothesis
B- Availibility of target
C- market prediction
D- Toxicology
Q44
Score: 0.5
A- Effect
B- Efficacy
C- Effectiveness
D- BENEFIT
Q45
Score: 0.5
صح
خطأ
Q46
Score: 0.5
A- pharmacodynamic drug- drug interaction
B- pharmacokinetic drug- drug interaction
C- pharmaceutic interaction
Q47
Score: 0.5
Q48
Score: 0.5
صح
خطأ
Q49
Score: 0.5
Q50
Score: 0.5
A- usually placebo controlled
B- phase IIa is exploratory and phase IIb is confirmatory
C- the opproxinate number of healthy subject is 50- 500
D- gives confirmation of clinical dose and regimen for efficacy
Q51
Score: 0.5
A- Easily
B- with difficult
C- poorly
D- non of the above
Q52
Score: 0.5
صح
خطأ
Q53
Score: 0.5
A- absorption
B- medication compliance
C- reduction in GI motility
D- Elimination
E- A+ D
F- all the above
Q54
Score: 0.5
A- producing hypotension
B- producing hypoglycemia
C- producing hypertension
D- producing hyperglycemia
Q55
Score: 0.5
صح
خطأ
Q56
Score: 0.5
A- albumin
B- alpha-1 acid glycoproteins
C- T cell
Q57
Score: 0.5
Q58
Score: 0.5
Q59
Score: 0.5
A- dose
B- Age
C- systemic toxicity
D- Route
Q60
Score: 0.5
A- structural
B- spontaneous
C- antidotal
D- route of exposure
Q61
Score: 0.5
A- mental retardation
B- Hyperactivity
C- all the above
D- non of the above
Q62
Score: 0.5
A- Health
B- disease
C- organization
D- non the above
Q63
Score: 0.5
A- pharmacodynamic
B- direct toxicity
C- genotoxicity
D- all the above
Q64
Score: 0.5
صح
خطأ
Q65
Score: 0.5
A- lethal dose to assayed in the same population
B- dose required for sub- lethal toxicity
C- all the above
Q66
Score: 0.5
A- Antibodies
B- vaccines
C- enzyme
D- DNA product
Q67
Score: 0.5
صح
خطأ
Q68
Score: 0.5
A- Arthritis
B-metabolism
C- peptic ulcer
D- stroke
Q69
Score: 0.5
صح
خطأ
Q70
Score: 0.5
A- check chemical stability
B- determine major metabolite
C- optimize and scale up synthesis and purification
D- produce GMP batches are required for biological and clinical test
Q71
Score: 0.5
A- transplant surgery
B- Apligraf
C- B cell
D- influenza
Q72
Score: 0.5
صح
خطأ
Q73
Score: 0.5
A- sulfonamide
B- Aspirin
C- Mepiridine
D- Benzodiazepine
Q74
Score: 0.5
صح
خطأ
Q75
Score: 0.5
صح
خطأ
Q76
Score: 0.5
A- pregnancy
B- cough
C- diarrhea
D- heart
Q77
Score: 0.5
Q78
Score: 0.5
صح
خطأ
Q79
Score: 0.5
A- drugs
B- food additives
C- cosmetic
D- pesticide
E- all of the above
Q80
Score: 0.5
Questions you haven't answered yet:
Are you sure you want to end this test and send your answers?
All copy rights reserved
©
arab-exams.com
2014-2023
Dismiss this alert